Symbols / KPRX Stock $2.35 -2.49% Kiora Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
KPRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Brian M. Strem Ph.D.
Exch · Country NCM · United States
Market Cap 10.31M
Enterprise Value -7.44M
Income -10.84M
Sales —
FCF (ttm) -9.19M
Book/sh 4.29
Cash/sh 4.33
Employees 13
Insider 10d —
IPO Feb 13, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.05
PEG —
P/S —
P/B 0.55
P/C —
EV/EBITDA 0.79
EV/Sales —
Quick Ratio 5.62
Current Ratio 5.99
Debt/Eq 2.28
LT Debt/Eq —
EPS (ttm) -2.64
EPS next Y -2.23
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-25
Earnings (prior) 2026-03-25
ROA -19.47%
ROE -51.74%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 4.39M
Shs Float 3.83M
Insider Own 3.08%
Instit Own 18.48%
Short Float 0.67%
Short Ratio 0.02
Short Interest 28.66K
52W High 4.18
vs 52W High -43.78%
52W Low 1.76
vs 52W Low 33.14%
Beta -0.77
Impl. Vol. —
Rel Volume 0.08
Avg Volume 508.75K
Volume 41.79K
Target (mean) $12.00
Tgt Median $12.00
Tgt Low $12.00
Tgt High $12.00
# Analysts 1
Recom None
Prev Close $2.41
Price $2.35
Change -2.49%
About

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.00
Mean price target
2. Current target
$2.35
Latest analyst target
3. DCF / Fair value
$-37.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.35
Low
$12.00
High
$12.00
Mean
$12.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-02 reit HC Wainwright & Co. Buy → Buy $10
2025-03-28 reit HC Wainwright & Co. Buy → Buy $10
2024-11-12 reit HC Wainwright & Co. Buy → Buy $10
2024-08-22 reit HC Wainwright & Co. Buy → Buy $10
2024-07-23 main HC Wainwright & Co. Buy → Buy $10
2024-05-20 reit HC Wainwright & Co. Buy → Buy $2
2024-03-27 main HC Wainwright & Co. Buy → Buy $2
2024-02-09 main HC Wainwright & Co. Buy → Buy $2
2023-11-13 reit HC Wainwright & Co. Buy → Buy $4
2023-11-06 main HC Wainwright & Co. Buy → Buy $4
2023-08-24 reit HC Wainwright & Co. Buy → Buy $2
2023-08-14 main HC Wainwright & Co. Buy → Buy $2
2023-08-09 main Maxim Group Buy → Buy $2
2023-05-12 main HC Wainwright & Co. Buy → Buy $7
2023-03-24 reit HC Wainwright & Co. — → Buy $6
2023-02-09 up Maxim Group Hold → Buy $12
2023-02-08 reit HC Wainwright & Co. — → Buy $10
2023-02-08 reit Ladenburg Thalmann — → Buy $119
News
RSS: Latest KPRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-06 STREM BRIAN M. Chief Executive Officer — 16,733 $0.00 $0
2026-03-06 DANIELS ERIC JOSEPH Officer — 6,533 $0.00 $0
2026-03-06 TOSCA MELISSA Chief Financial Officer — 6,533 $0.00 $0
2025-04-01 STREM BRIAN M. Chief Executive Officer — 15,941 $0.00 $0
2025-04-01 DANIELS ERIC JOSEPH Officer — 7,772 $0.00 $0
2025-04-01 TOSCA MELISSA Chief Financial Officer — 7,772 $0.00 $0
2024-09-11 STENGONE CARMINE N Director — 1,250 $3.68 $4,600
2024-09-10 SHAPIRO ARON Director — 3,000 $3.60 $10,800
2024-08-19 TYLE PRAVEEN Director — 5,000 $3.96 $19,800
2024-08-19 WALTERS-HOFFERT LISA Director — 1,250 $3.86 $4,825
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
16.00
0.00
0.00
Operating Revenue
0.00
-100.00%
16.00
0.00
0.00
Operating Expense
9.46
-9.21%
10.42
+19.90%
8.69
-25.90%
11.73
Research And Development
3.71
-24.15%
4.90
+21.60%
4.03
+16.76%
3.45
Selling General And Administration
5.75
+3.66%
5.54
+18.85%
4.66
-43.67%
8.28
General And Administrative Expense
5.75
+3.66%
5.54
+18.85%
4.66
-43.67%
8.28
Other Gand A
5.75
+3.66%
5.54
+18.85%
4.66
-43.67%
8.28
Other Operating Expenses
—
-0.02
—
—
Total Expenses
9.46
-9.21%
10.42
+19.90%
8.69
-25.90%
11.73
Operating Income
-9.46
-269.50%
5.58
+164.22%
-8.69
+25.90%
-11.73
Total Operating Income As Reported
-12.83
-384.48%
4.51
+135.83%
-12.59
-2.25%
-12.31
EBITDA
-12.07
-311.78%
5.70
+146.12%
-12.36
+9.42%
-13.65
Normalized EBITDA
-8.70
-226.48%
6.88
+181.55%
-8.44
+27.55%
-11.64
Reconciled Depreciation
0.02
+29.14%
0.02
-62.92%
0.05
+24.49%
0.04
EBIT
-12.10
-312.94%
5.68
+145.77%
-12.41
+9.32%
-13.69
Total Unusual Items
-3.37
-186.10%
-1.18
+69.97%
-3.93
-95.91%
-2.00
Total Unusual Items Excluding Goodwill
-3.37
-186.10%
-1.18
+69.97%
-3.93
-95.91%
-2.00
Special Income Charges
-3.37
-186.10%
-1.18
+69.97%
-3.93
-578.62%
-0.58
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
0.00
-100.00%
0.10
—
0.00
Restructuring And Mergern Acquisition
-1.25
-33.57%
-0.94
-147.05%
1.99
+241.98%
0.58
Write Off
4.62
+130.28%
2.01
+5.44%
1.90
0.00
Net Income
-10.84
-401.42%
3.59
+128.73%
-12.51
+7.88%
-13.58
Pretax Income
-12.12
-314.10%
5.66
+145.56%
-12.42
+9.29%
-13.70
Net Non Operating Interest Income Expense
0.87
-29.02%
1.23
+656.13%
0.16
+237.23%
0.05
Interest Expense Non Operating
0.02
-6.93%
0.02
+92.65%
0.01
+29.46%
0.01
Net Interest Income
0.87
-29.02%
1.23
+656.13%
0.16
+237.23%
0.05
Interest Expense
0.02
-6.93%
0.02
+92.65%
0.01
+29.46%
0.01
Interest Income Non Operating
0.89
-28.64%
1.25
+620.07%
0.17
+205.83%
0.06
Interest Income
0.89
-28.64%
1.25
+620.07%
0.17
+205.83%
0.06
Other Income Expense
-3.53
-206.48%
-1.15
+70.42%
-3.90
-93.08%
-2.02
Other Non Operating Income Expenses
-0.16
-714.70%
0.03
-9.60%
0.03
+298.93%
-0.01
Gain On Sale Of Security
—
—
—
-1.43
Gain On Sale Of Business
—
—
—
—
Tax Provision
-1.28
-162.09%
2.07
+2186.35%
0.09
+179.92%
-0.11
Tax Rate For Calcs
0.00
-71.04%
0.00
+72.67%
0.00
+636.84%
0.00
Tax Effect Of Unusual Items
-0.35
+17.15%
-0.43
+48.15%
-0.82
-1343.56%
-0.06
Net Income Including Noncontrolling Interests
-10.84
-401.42%
3.59
+128.73%
-12.51
+7.88%
-13.58
Net Income From Continuing Operation Net Minority Interest
-10.84
-401.42%
3.59
+128.73%
-12.51
+7.88%
-13.58
Net Income From Continuing And Discontinued Operation
-10.84
-401.42%
3.59
+128.73%
-12.51
+7.88%
-13.58
Net Income Continuous Operations
-10.84
-401.42%
3.59
+128.73%
-12.51
+7.88%
-13.58
Normalized Income
-7.82
-279.88%
4.35
+146.17%
-9.41
+19.11%
-11.64
Net Income Common Stockholders
-10.84
-401.42%
3.59
+127.56%
-13.04
+3.97%
-13.58
Otherunder Preferred Stock Dividend
—
0.00
-100.00%
0.53
0.00
Diluted EPS
—
0.87
+103.59%
-24.25
+85.47%
-166.95
Basic EPS
—
0.93
+103.84%
-24.25
+85.47%
-166.95
Basic Average Shares
—
3.87
+619.81%
0.54
+561.22%
0.08
Diluted Average Shares
—
4.13
+666.73%
0.54
+561.22%
0.08
Diluted NI Availto Com Stockholders
-10.84
-401.42%
3.59
+127.56%
-13.04
+3.97%
-13.58
Gain On Sale Of PPE
0.00
+100.00%
-0.00
+86.40%
-0.03
-773.93%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
24.25
-33.52%
36.48
+166.08%
13.71
-26.59%
18.68
Current Assets
21.75
-26.79%
29.71
+526.97%
4.74
-38.31%
7.68
Cash Cash Equivalents And Short Term Investments
17.09
-36.22%
26.79
+991.47%
2.45
-58.85%
5.96
Cash And Cash Equivalents
8.70
+129.32%
3.79
+54.49%
2.45
-58.85%
5.96
Other Short Term Investments
8.39
-63.51%
23.00
0.00
—
Receivables
3.32
+280.54%
0.87
-57.49%
2.05
+49.30%
1.37
Other Receivables
1.52
+153.29%
0.60
—
—
Taxes Receivable
1.79
+563.64%
0.27
-86.82%
2.05
+49.30%
1.37
Prepaid Assets
0.20
0.00
—
—
Other Current Assets
1.14
-44.10%
2.04
+775.17%
0.23
-31.97%
0.34
Total Non Current Assets
2.50
-63.05%
6.78
-24.46%
8.97
-18.40%
11.00
Net PPE
0.38
+504.95%
0.06
-45.72%
0.11
-33.23%
0.17
Gross PPE
0.40
+536.03%
0.06
-47.69%
0.12
-58.12%
0.29
Accumulated Depreciation
-0.03
-2430.47%
-0.00
+83.72%
-0.01
+94.64%
-0.12
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.01
+8.62%
0.01
+148.16%
0.00
-95.90%
0.06
Other Properties
0.29
+399.96%
0.06
-51.85%
0.12
-42.20%
0.21
Leases
0.11
0.00
0.00
-100.00%
0.02
Goodwill And Other Intangible Assets
2.06
-69.15%
6.69
-24.13%
8.81
-17.96%
10.74
Goodwill
—
—
—
—
Other Intangible Assets
2.06
-69.15%
6.69
-24.13%
8.81
-17.96%
10.74
Other Non Current Assets
0.06
+121.79%
0.03
-35.67%
0.05
-45.25%
0.08
Total Liabilities Net Minority Interest
8.13
-24.22%
10.72
+41.07%
7.60
+4.56%
7.27
Current Liabilities
3.63
-39.56%
6.01
+267.73%
1.63
-50.07%
3.27
Payables And Accrued Expenses
3.47
-42.07%
5.99
+277.17%
1.59
-44.20%
2.84
Payables
1.20
-56.17%
2.74
+1230.18%
0.21
-79.54%
1.01
Accounts Payable
1.06
+155.13%
0.42
+101.49%
0.21
-79.54%
1.01
Current Accrued Expenses
2.26
-30.14%
3.24
+134.79%
1.38
-24.80%
1.84
Total Tax Payable
0.14
-93.90%
2.33
0.00
—
Income Tax Payable
0.14
-93.90%
2.33
0.00
—
Current Debt And Capital Lease Obligation
0.16
+604.18%
0.02
-50.38%
0.05
-55.50%
0.11
Current Capital Lease Obligation
0.16
+604.18%
0.02
-50.38%
0.05
-55.50%
0.11
Other Current Liabilities
—
—
—
0.32
Total Non Current Liabilities Net Minority Interest
4.50
-4.68%
4.72
-20.98%
5.97
+49.27%
4.00
Long Term Debt And Capital Lease Obligation
0.20
+502.69%
0.03
-43.47%
0.06
0.00
Long Term Capital Lease Obligation
0.20
+502.69%
0.03
-43.47%
0.06
0.00
Non Current Deferred Liabilities
1.35
+175.56%
0.49
-37.05%
0.78
+13.11%
0.69
Non Current Deferred Revenue
1.25
0.00
—
—
Non Current Deferred Taxes Liabilities
0.10
-79.18%
0.49
-37.05%
0.78
+13.11%
0.69
Other Non Current Liabilities
2.94
-29.87%
4.19
-18.28%
5.13
+54.99%
3.31
Stockholders Equity
16.13
-37.40%
25.76
+321.62%
6.11
-46.44%
11.41
Common Stock Equity
16.13
-37.40%
25.76
+321.62%
6.11
-46.44%
11.41
Capital Stock
0.28
+2.84%
0.27
+247.27%
0.08
+328.57%
0.02
Common Stock
0.28
+2.84%
0.27
+247.28%
0.08
+328.54%
0.02
Preferred Stock
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Share Issued
3.76
+25.36%
3.00
+250.48%
0.86
+328.93%
0.20
Ordinary Shares Number
3.76
+25.36%
3.00
+250.48%
0.86
+328.93%
0.20
Additional Paid In Capital
170.31
+0.68%
169.16
+10.42%
153.19
+4.90%
146.04
Retained Earnings
-154.22
-7.56%
-143.38
+2.45%
-146.98
-9.31%
-134.46
Gains Losses Not Affecting Retained Earnings
-0.25
+12.77%
-0.28
-54.35%
-0.18
-0.03%
-0.18
Other Equity Adjustments
-0.25
+12.77%
-0.28
-54.35%
-0.18
-0.03%
-0.18
Total Equity Gross Minority Interest
16.13
-37.40%
25.76
+321.62%
6.11
-46.44%
11.41
Total Capitalization
16.13
-37.40%
25.76
+321.62%
6.11
-46.44%
11.41
Working Capital
18.12
-23.55%
23.70
+663.44%
3.10
-29.59%
4.41
Invested Capital
16.13
-37.40%
25.76
+321.62%
6.11
-46.44%
11.41
Total Debt
0.37
+544.15%
0.06
-46.52%
0.11
+1.05%
0.11
Capital Lease Obligations
0.37
+544.15%
0.06
-46.52%
0.11
+1.05%
0.11
Net Tangible Assets
14.06
-26.26%
19.07
+805.30%
-2.70
-506.99%
0.66
Tangible Book Value
14.06
-26.26%
19.07
+805.30%
-2.70
-506.99%
0.66
Preferred Stock Equity
0.00
+0.00%
0.00
+0.00%
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-9.96
-216.38%
8.56
+189.56%
-9.56
+8.35%
-10.43
Cash Flow From Continuing Operating Activities
-9.96
-216.38%
8.56
+189.56%
-9.56
+8.35%
-10.43
Net Income From Continuing Operations
-10.84
-401.42%
3.59
+128.73%
-12.51
+7.88%
-13.58
Depreciation Amortization Depletion
0.02
+29.14%
0.02
-62.92%
0.05
+24.49%
0.04
Depreciation
—
—
—
—
Amortization Cash Flow
0.02
+29.14%
0.02
-62.92%
0.05
—
Depreciation And Amortization
0.02
+29.14%
0.02
-62.92%
0.05
+24.49%
0.04
Amortization Of Intangibles
0.02
+29.14%
0.02
-62.92%
0.05
—
Other Non Cash Items
-0.90
+1.68%
-0.92
-145.77%
2.00
+196.73%
0.68
Stock Based Compensation
0.90
+37.11%
0.66
-13.03%
0.75
+63.25%
0.46
Asset Impairment Charge
4.62
+118.92%
2.11
+10.91%
1.90
0.00
Deferred Tax
-0.39
-34.56%
-0.29
-419.70%
0.09
+179.92%
-0.11
Deferred Income Tax
-0.39
-34.56%
-0.29
-419.70%
0.09
+179.92%
-0.11
Operating Gains Losses
-0.00
-212.38%
-0.00
+97.02%
-0.03
-101.79%
1.42
Gain Loss On Investment Securities
-0.00
+47.53%
-0.00
—
1.43
Unrealized Gain Loss On Investment Securities
-0.00
-200.00%
0.00
0.00
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.00
-86.75%
0.03
+773.93%
-0.00
Change In Working Capital
-3.27
-189.21%
3.67
+301.22%
-1.82
-372.54%
0.67
Change In Receivables
-2.41
-333.71%
1.03
+288.51%
-0.55
+37.20%
-0.87
Change In Prepaid Assets
0.42
+123.01%
-1.82
-206190.06%
0.00
-99.68%
0.28
Change In Payables And Accrued Expense
-2.39
-153.19%
4.49
+454.02%
-1.27
-191.06%
1.39
Change In Accrued Expense
-3.51
-182.41%
4.26
+1027.07%
-0.46
-175.40%
0.61
Change In Payable
1.12
+397.49%
0.23
+127.98%
-0.81
-203.27%
0.78
Change In Account Payable
1.12
+397.49%
0.23
+127.98%
-0.81
-203.27%
0.78
Change In Other Working Capital
1.25
—
—
—
Change In Other Current Assets
-0.03
-324.36%
0.02
+300.86%
-0.01
+66.25%
-0.02
Change In Other Current Liabilities
-0.10
-123.32%
-0.05
-8062.33%
0.00
+100.56%
-0.10
Investing Cash Flow
14.43
+163.66%
-22.66
0.00
-100.00%
0.01
Cash Flow From Continuing Investing Activities
14.43
+163.66%
-22.66
0.00
-100.00%
0.01
Net PPE Purchase And Sale
-0.11
-1670.92%
-0.01
0.00
-100.00%
0.01
Purchase Of PPE
-0.11
-1670.92%
-0.01
0.00
0.00
Sale Of PPE
—
—
0.00
-100.00%
0.01
Capital Expenditure
-0.11
-1670.92%
-0.01
—
—
Net Investment Purchase And Sale
14.54
+164.16%
-22.66
0.00
—
Purchase Of Investment
-8.18
+77.05%
-35.63
0.00
—
Sale Of Investment
22.71
+75.04%
12.98
0.00
—
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Gain Loss On Sale Of Business
—
0.00
+100.00%
-0.05
0.00
Financing Cash Flow
0.27
-98.29%
15.50
+159.77%
5.97
-30.80%
8.62
Cash Flow From Continuing Financing Activities
0.27
-98.29%
15.50
+159.77%
5.97
-30.80%
8.62
Net Issuance Payments Of Debt
0.00
0.00
—
0.00
Issuance Of Debt
2.75
0.00
—
—
Repayment Of Debt
-2.75
0.00
—
0.00
Long Term Debt Issuance
2.75
0.00
—
—
Long Term Debt Payments
-2.75
0.00
—
0.00
Net Long Term Debt Issuance
0.00
0.00
—
0.00
Net Common Stock Issuance
0.00
-100.00%
15.00
+115.27%
6.97
+29.94%
5.36
Common Stock Payments
—
—
0.00
+100.00%
-0.02
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-0.02
Proceeds From Stock Option Exercised
0.27
-84.27%
1.69
+450.13%
0.31
-90.58%
3.26
Net Other Financing Charges
—
-1.19
+9.04%
-1.31
—
Changes In Cash
4.73
+239.23%
1.39
+138.84%
-3.59
-99.40%
-1.80
Effect Of Exchange Rate Changes
0.17
+403.39%
-0.06
-258.89%
0.04
+142.36%
-0.09
Beginning Cash Position
3.80
+54.39%
2.46
-59.11%
6.01
-23.87%
7.90
End Cash Position
8.70
+129.20%
3.80
+54.39%
2.46
-59.11%
6.01
Free Cash Flow
-10.07
-217.76%
8.55
+189.49%
-9.56
+8.35%
-10.43
Amortization Of Securities
-0.11
+60.38%
-0.28
0.00
—
Common Stock Issuance
0.00
-100.00%
15.00
+115.27%
6.97
+29.56%
5.38
Issuance Of Capital Stock
0.00
-100.00%
15.00
+115.27%
6.97
+29.56%
5.38
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category